FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 235 filers reported holding FATE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,060,000 | +44437.8% | 500,000 | 0.0% | 0.06% | -49.1% |
Q2 2023 | $2,380 | -16.5% | 500,000 | 0.0% | 0.11% | -21.4% |
Q1 2023 | $2,850 | -100.0% | 500,000 | -60.0% | 0.14% | -78.9% |
Q4 2022 | $12,612,500 | +60.8% | 1,250,000 | +257.1% | 0.66% | +50.8% |
Q3 2022 | $7,844,000 | -36.7% | 350,000 | -30.0% | 0.44% | -43.8% |
Q2 2022 | $12,390,000 | -36.1% | 500,000 | 0.0% | 0.78% | -21.2% |
Q1 2022 | $19,385,000 | -33.7% | 500,000 | 0.0% | 1.00% | -12.3% |
Q4 2021 | $29,255,000 | – | 500,000 | – | 1.14% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Polaris Venture Management Co. V, L.L.C. | 569,889 | $46,987,000 | 60.92% |
Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $278,604,000 | 36.08% |
Darwin Global Management, Ltd. | 1,370,133 | $112,967,000 | 22.12% |
Redmile Group, LLC | 12,957,222 | $1,068,323,000 | 15.05% |
Copernicus Capital Management, LLC | 8,000 | $660,000 | 10.66% |
Casdin Capital, LLC | 3,400,000 | $280,330,000 | 8.35% |
Grosvenor Holdings, L.L.C. | 1,123,576 | $92,639,000 | 6.81% |
DAFNA Capital Management LLC | 314,360 | $25,919,000 | 6.15% |
Ally Bridge Group (NY) LLC | 270,000 | $22,262,000 | 4.27% |
Ghost Tree Capital, LLC | 185,000 | $15,253,000 | 3.58% |